Philosophy of Care
Dr. Swislocki's research interests include disorders of insulin resistance, specifically: Hypertension, diabetes mellitus, complications of diabetes mellitus, and pathophysiology of insulin resistance.
He is also interested in delivery of health care to people with chronic metabolic diseases, including diabetes, hypertension, and osteoporosis.
Dr. Swislocki is board-certified in Internal Medicine and Endocrinology and Metabolism. His practice is by referral and almost entirely clinic-based.
His primary interest is in disorders of insulin resistance, such as hypertension, diabetes, and diabetes complications, but he is also interested in caring for patients with chronic metabolic diseases such as obesity and osteoporosis, as well as more general endocrinologic disorders.
Dr. Swislocki is currently a member of the VA VISN 21 Endocrine Task Force addressing appropriate goals of therapy, and safety issues, for diabetes and male hypogonadism, and other endocrine and metabolic disorders.
He is also part of a national VA Transgender Working Group focused on providing consistent, mutiispecialty, state-of-the-art care for Trans Veterans.
Endocrinology, Diabetes, and Metabolism
M.D., UCLA School of Medicine, Los Angeles CA 1979
B.A., UCLA, Los Angeles CA 1972
M.A., UCLA, Los Angeles CA 1973
Internship: LA County/USC Medical Center, Los Angeles CA 1979-1980
UC Davis Medical Center, Sacramento CA 1980-1982
UC Davis Medical Center (Chief Resident), Sacramento CA 1982-1983
Stanford University Medical Center, Stanford CA 1984-1986
American Board of Endocrinology, Diabetes and Metabolism, 1989
American Board of Internal Medicine, 1982
American College of Physicians
American Diabetes Association
American Federation for Medical Research
The Endocrine Society
Honors and Awards
Member, VISN 21 Endocrinology Advisory Board, 2012
Recognition as an "Outstanding Reviewer," by the Editor, Annals of Internal Medicine, 2009
Recognition as an "Outstanding Reviewer," by the Editor, Annals of Internal Medicine, 2008
Attending of the year, Medical Service, Martinez DVAMC, 1990
Select Recent Publications
Holman, R., B. Park, T. Slade, Tyler, M. Murdock, K. Rodnick, and A. Swislocki. A biochemistry question-guided derivation of a potential mechanism for HbA1c formation in diabetes mellitus leading to a data-driven clinical diagnosis. The Journal of Chemical Education. 2016.
Atterado, S., G. Ono, S. Kanehira-Mar, J. Meier, and A. Swislocki. Evaluating Vitamin D Repletion Regimens and Effects in Veteran Patients. Annals of Pharmacotherapy, 2015;49:969-77.
Swislocki, A., and I. Jialal. Perspective: The Novel Role of the Kidney in Diabetes Management: SGLT-2 Inhibitors. Metabolic Syndrome and Related Disorders, 2015;13:287-91.
LaFleur J., C.L. Steenhoek, J. Horne, J. Meier, J. Nebeker, S. Mambourg, A. Swislocki, and J. Carmichael (2015). Comparing Fracture Absolute Risk Assessment (FARA) Tools: An Osteoporosis Clinical Informatics Tool to Improve Identification and Care of Males at High Risk of First Fracture. Annals of Pharmacotherapy, 2015;49:506-14.
Leary, J., and A. Swislocki. Hypothalamic-Pituitary-Adrenal Suppression and Iatrogenic Cushing's as a Complication of Epidural Steroid Injections. Case Rep Endocrinol. 2013:617042. Epub 2013 Aug 7.
Chock, B., T.-C. Lin, C.-S. Li, and A. Swislocki. Plasma Testosterone is Associated with Framingham Risk Score. Aging Male. 2012;15:134-39.
Swislocki, A., and D. Siegel. Hypertensive Treatment and the Metabolic Syndrome. Current Hypertension Reviews; 2011;7:172-83.
Kelley, D.S., Y. Adkins, L. R Woodhouse, A. Swislocki, B. E. Mackey, and D. Siegel (2012). DHA Supplementation Improved Lipocentric But Not Glucocentric Markers of Insulin Sensitivity in Hypertriglyceridemic Men. Metab Syndr Relat Disord; 10: 32-38.
Swislocki, A.L.M., J.L. Meier, S.M. Najera, and R. H. Noth (2011). Long-term maintenance of glucose control in veterans with type 2 diabetes mellitus using oral agents. Metab Syndr Relat Disord; 9: 469-73.
Swislocki, A.L.M., D. Siegel, and I. Jialal (2012). Pharmacotherapy for the Metabolic Syndrome. Invited Review, Curr Vasc Pharmacol; 10: 187-205.